<bill session="115" type="s" number="3738" updated="2019-07-16T21:20:12Z">
  <state datetime="2018-12-11">REFERRED</state>
  <status>
    <introduced datetime="2018-12-11"/>
  </status>
  <introduced datetime="2018-12-11"/>
  <titles>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act and Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.</title>
    <title type="short" as="introduced">Hatch-Waxman Integrity Act of 2018</title>
    <title type="short" as="introduced">Hatch-Waxman Integrity Act of 2018</title>
    <title type="display">Hatch-Waxman Integrity Act of 2018</title>
  </titles>
  <sponsor bioguide_id="H000338"/>
  <cosponsors>
    <cosponsor bioguide_id="T000476" joined="2018-12-11"/>
  </cosponsors>
  <actions>
    <action datetime="2018-12-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2018-12-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="115" relation="identical" number="7251"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Fraud offenses and financial crimes"/>
    <term name="Intellectual property"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
    <term name="Securities"/>
  </subjects>
  <amendments/>
  <summary date="2018-12-11T05:00:00Z" status="Introduced in Senate">Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.</summary>
  <committee-reports/>
</bill>
